CytoAgents

CytoAgents Announces Completion of Cohort 1 Dose-escalation Stage of Clinical Phase 1B to Advance Research on Cytokine Release Syndrome

Leslie BHA2025-04-25T11:50:18-04:00PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose-escalation to the next, higher planned dose in Cohort 2. “This milestone marks an important step forward in our mission to deliver a safe, effective therapy...

PITTSBURGH TECHNOLOGY COUNCIL TECH50

Antonette Ho2024-09-30T02:00:09-04:00The Pittsburgh Technology Council's Tech 50 Awards honors technology innovation in our region. On Thursday, November 14, 2024, we will celebrate the most successful and innovative companies in Southwestern Pennsylvania at the 28th annual Tech 50 Awards! Congratulations to our 2024 Finalists! MedTech/Life Sciences - CytoAgents. CEO of the Year - CytoAgents: Teresa Whalen, CEO. Read more >>

CytoAgents Receives Third Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

Antonette Ho2024-09-30T02:09:19-04:00CytoAgents Inc., a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the third NIH grant in four years. This funding will accelerate the development of its lead drug candidate, CTO1681, an investigational new drug that uses a novel approach designed to prevent and mitigate Cytokine Release Syndrome in patients receiving CAR T-Cell therapy. This is an...

CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy

Antonette Ho2023-10-26T21:11:54-04:00CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated recruitment and will enroll its first patient at UPMC Hillman Cancer Center, in the Phase 1b/2a clinical trial evaluating the therapeutic, CTO1681, to treat CRS in lymphoma patients receiving CAR T-cell Therapy. “This clinical trial (CTA-2101) addresses an area of great unmet medical need as the majority of patients receiving CAR T-cell Therapy experience the toxicities of CRS...

CytoAgents reaches FDA milestone and closes on $7 million funding round led by PCG Capital

Antonette Ho2023-05-23T00:27:46-04:00A Pittsburgh-based biotech startup announced it reached the next milestone in its pursuit of full U.S. Food and Drug Administration (FDA) approval for its drug that looks to aid cancer patients undergoing immunotherapy treatment. This new clearance for CytoAgents Inc., which employs four people full-time, comes just days after the startup closed on a $7 million Series A2 equity-based funding round, which Pittsburgh-based PCG Capital led with support from BlueTree Allied Angels and a syndicate of local oncologists. It brings...

CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology

Antonette Ho2023-05-16T23:58:44-04:00CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA). This clearance enables the initiation of a U.S. Phase 1b/2a clinical trial under its Investigational New Drug (IND) application for the therapeutic, CTO1681, to treat CRS in lymphoma patients receiving CAR T-Cell Therapy. This is an area of great unmet medical need as the majority...

EY Announces Teresa Whalen, RPh, CEO of CytoAgents as an Entrepreneur Of The Year® 2023 East Central Award Finalist

Antonette Ho2023-05-05T23:53:45-04:00Ernst & Young LLP (EY US) today announced that Teresa Whalen, RPh, CEO of CytoAgents, was named an Entrepreneur Of The Year® 2023 East Central Award finalist. Now in its 37th year, Entrepreneur Of The Year is one of the preeminent competitive business awards for transformative entrepreneurs and leaders of high-growth companies who are building a more equitable, sustainable and prosperous world for all. Whalen was selected by an independent panel of judges. Entrepreneurs were evaluated based on their demonstration...

The pandemic changed how Pittsburgh’s life sciences startups get funded

Antonette Ho2023-04-30T20:41:54-04:00CytoAgents CEO Teresa Whalen, BioHybrid Solutions CEO Jean Pineault and NeuBase Therapeutics CEO Dietrich Stephan agree: COVID-19 radically changed the way their industry operates. During a BioBreakfast panel on Tuesday morning, part of Pittsburgh’s XchangeInnovation Week, the life sciences CEOs shared their pandemic experiences, why they chose to do business in this region, and what advice they had for anyone considering starting or working at a life sciences company. In Whalen’s case, one of the biggest changes was suddenly needing...

Companies To Watch: CytoAgents

Ziad2022-11-25T13:59:44-05:00CytoAgents primarily focuses on developing a single lead drug, coded CTO1681, in multiple indications involving cytokine release syndrome (CRS). Simply stated, CRS is “an overreaction of the immune system, commonly known as cytokine storm.” It has many causes and affects many areas and systems of the body. CTO1681 targets the NF-kB (nuclear factor kappa B) signaling pathway to modulate cytokine production, thus reducing inflammation. CytoAgents has early programs in four areas: oncology (with CAR T-cell therapy), dermatology (atopic dermatitis), neurology...

CytoAgents Announces Appointment of New Chief Medical Officer

Ziad2022-11-25T13:59:44-05:00CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. Bertolino is a seasoned senior pharmaceuticals executive who has led clinical development and business growth for early-stage biotechnology as well as mid-sized and large pharmaceutical companies. Through extensive domestic and international management and drug development experience, including C-level roles...